Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -569.59%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-319.71%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-247.30%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-205.73%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-128.04%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Processa Pharmaceuticals, Inc.
Market Cap
$4.04M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-319.71%
3Y Avg
-247.30%
5Y Avg
-205.73%
Market Cap
$3.93M
Return on Invested Capital (ROIC)
-288.14%
TTM Avg
-190.86%
3Y Avg
-162.44%
5Y Avg
-129.35%
Market Cap
$4.18M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-199.78%
3Y Avg
-1598.70%
5Y Avg
-1598.70%
Market Cap
$3.90M
Return on Invested Capital (ROIC)
-321.28%
TTM Avg
-227.99%
3Y Avg
-186.65%
5Y Avg
-145.51%
Market Cap
$4.21M
Return on Invested Capital (ROIC)
-221.32%
TTM Avg
-119.11%
3Y Avg
-77.97%
5Y Avg
-64.48%
Market Cap
$4.32M
Return on Invested Capital (ROIC)
-116.89%
TTM Avg
-117.72%
3Y Avg
-83.78%
5Y Avg
-61.46%
Market Cap
$3.53M
Return on Invested Capital (ROIC)
-284.81%
TTM Avg
-319.42%
3Y Avg
-246.02%
5Y Avg
-246.02%
Market Cap
$3.67M
Return on Invested Capital (ROIC)
-346.94%
TTM Avg
-467.60%
3Y Avg
-296.93%
5Y Avg
-277.74%
Market Cap
$3.63M
Return on Invested Capital (ROIC)
-9.04%
TTM Avg
-9.04%
3Y Avg
-6.72%
5Y Avg
4.87%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | $4.04M | N/A | -319.71% | -247.30% | -205.73% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | -288.14% | -190.86% | -162.44% | -129.35% |
| GRI Bio, Inc. (GRI)vs › | $4.18M | N/A | -199.78% | -1598.70% | -1598.70% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.90M | -321.28% | -227.99% | -186.65% | -145.51% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.21M | -221.32% | -119.11% | -77.97% | -64.48% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | -116.89% | -117.72% | -83.78% | -61.46% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | -284.81% | -319.42% | -246.02% | -246.02% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.67M | -346.94% | -467.60% | -296.93% | -277.74% |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | -9.04% | -9.04% | -6.72% | 4.87% |
| Evogene Ltd. (EVGN)vs › | $3.65M | -130.12% | -72.08% | -61.96% | -55.38% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-03-31 | -569.59% |
| 2025-12-31 | -250.81% |
| 2025-09-30 | -223.21% |
| 2025-06-30 | -212.16% |
| 2025-03-31 | -342.78% |
| 2024-12-31 | -710.29% |
| 2024-09-30 | -316.57% |
| 2024-06-30 | -174.05% |
| 2024-03-31 | -113.73% |
| 2023-12-31 | -226.60% |
| 2023-09-30 | -303.93% |
| 2023-06-30 | -279.91% |
| 2023-03-31 | -276.51% |
| 2022-12-31 | -361.16% |
| 2022-09-30 | -102.38% |
| 2022-06-30 | -74.08% |
| 2022-03-31 | -56.66% |
| 2021-12-31 | -47.60% |
| 2021-09-30 | -68.92% |
| 2021-06-30 | -63.39% |
| 2021-03-31 | -50.46% |
| 2020-12-31 | -62.78% |
| 2020-09-30 | -66.66% |
| 2020-06-30 | -39.03% |
| 2020-03-31 | -42.21% |
| 2019-12-31 | -37.50% |
| 2019-09-30 | -35.76% |
| 2019-06-30 | -35.57% |
| 2019-03-31 | -35.53% |
| 2018-12-31 | -35.35% |
| 2018-09-30 | -41.52% |
| 2018-06-30 | -32.10% |
| 2018-03-31 | -24.60% |
| 2017-12-31 | -63.65% |
| 2015-09-30 | -11576.25% |
| 2015-06-30 | -1252.34% |
| 2015-03-31 | -164.48% |
| 2014-12-31 | -191.86% |
| 2014-09-30 | -145.36% |
| 2014-06-30 | -138.62% |
| 2014-03-31 | -129.26% |
| 2013-12-31 | -120.99% |
| 2013-09-30 | -82.38% |
| 2013-06-30 | -90.94% |
| 2013-03-31 | -89.08% |
| 2012-12-31 | -61.70% |
| 2012-09-30 | -48.72% |
